HCoV-229E |
Alpha-coronavirus |
General malaise, headache, nasal discharge, sneezing, sore throat, fever, and cough. |
2–5 days |
1966 |
N/A |
[47], [189], [190]
|
HCoVOC43 |
Beta-coronavirus |
General malaise, headache, nasal discharge, sneezing, sore throat, fever, and cough. |
2–5 days |
1967 |
N/A |
[191], [192]
|
HCoV-NL63 |
Alpha-coronavirus |
Mild respiratory disease is similar to the common cold, cough, rhinorrhea, tachypnea, fever, hypoxia, obstructive laryngitis (croup). |
2–4 days |
2004 |
N/A |
[193], [194], [195]
|
HCoV-HKU1 |
Beta-coronavirus |
Upper respiratory tract fever, running nose, and cough lower respiratory tract, fever, productive cough, and dyspnea. |
2–4 days |
2005 |
N/A |
[196], [197]
|
Severe acute respiratory syndrome coronavirus (SARS-CoV). |
Beta-coronavirus |
Fever > 37.8 °C (100,0°F), chills, headache, malaise, myalgia, lethargy, sore throat, pneumonia (direct viral or secondary bacterial), non-productive cough, dyspnea, respiratory distress, Diarrhea (30–40% of patients). |
2–14 days |
2003 |
9% died, much higher for those over 60 years old, with mortality rates approaching 50% for this subset of patients |
[198] |
Middle East respiratory syndrome coronavirus |
Beta-coronavirus |
A severe respiratory illness characterized by fever, cough dyspnea, chills, sore throat, myalgia, arthralgia, pneumonia, diarrhea and vomiting (one-third of patients), acute renal impairment. |
2–13 days |
2012 |
The case fatality rate is 35–40% |
[134], [199], [200], [201], [202]
|
Novel coronavirus COVID-19 |
Beta- coronavirus |
Asymptomatic, mild infection: fever, dry cough, malaise, dehydration.Severe infection: high fever, shortness of breath, chest pain, hemoptysis |
2–14 days |
2019 |
~ 468,644 cases (Dec 2019 – March 2020) |
[203], [204], [205]
|